What is the history of Viatris?

Viatris has a relatively recent history, having been established in November 2020 through the merger of Mylan and Upjohn, a division of Pfizer. This strategic merger combined Mylan's extensive portfolio of generic and specialty pharmaceuticals with Upjohn's established brands and off-patent medicines. The creation of Viatris aimed to enhance access to high-quality medicines while addressing the evolving healthcare landscape and the needs of patients worldwide. Mylan was founded in 1961 and became one of the world's leading generics and specialty pharmaceuticals companies, known for its commitment to quality and affordability. It had a robust presence in various therapeutic categories and a wide-ranging product portfolio. Upjohn, on the other hand, was formed to focus on legacy established medicines that were losing patent protection. Upjohn had a long-standing history as part of Pfizer, known for several well-known pharmaceuticals. The merger into Viatris was driven by the vision of providing access to medicines for patients globally, bridging gaps in healthcare systems and ensuring that more people could receive the treatments they needed. Viatris now operates with a mission centered on empowering people worldwide to live healthier at every stage of life. The company's operations encompass a broad range of therapeutic areas, and it continues to build its capabilities to enhance patient access and improve health outcomes. For more detailed information on Viatris' history, it might be beneficial to visit their official website, as they provide a comprehensive overview of their background, achievements, and ongoing initiatives.